Pyrogens

Bacterial lipopolysaccharide acts as an exogenous pyrogen that activates immune cells. These cells release endogenous cytokines, including interleukin-1 and tumor necrosis factor. The signals then promote prostaglandin E2 production in the hypothalamus, which raises the body’s temperature set point. This sequence links contamination with the regulated physiological response recognized as fever.

Exogenous pyrogens originate outside the body, with bacterial lipopolysaccharide serving as an important example. Endogenous pyrogens are fever-associated cytokine signals produced by the body after immune-cell activation, including interleukin-1 and tumor necrosis factor. Distinguishing the initiating contaminant from the host mediators clarifies how an external product impurity can produce a systemic clinical response.

Prostaglandin E2 provides a key signaling step between cytokine release and the fever response. After immune activation, increased prostaglandin E2 production in the hypothalamus raises the body’s temperature set point rather than simply adding heat to the body. This mechanism explains why pyrogen exposure can produce a coordinated temperature increase and broader inflammatory consequences.

Clinical pyrogen testing examines injectable drugs, biologics, and medical devices for fever-producing contamination. The overview identifies bacterial endotoxin assays and in vivo rabbit tests as approaches used for this purpose. These methods provide a way to assess whether a product may provoke a fever response before or during its use in clinical care and pharmaceutical manufacturing.

Pyrogen control is especially relevant to injectable drugs, biologics, and medical devices because contaminants associated with these products may enter the body directly. Testing focuses on detecting fever-producing substances, including bacterial endotoxin. Incorporating this evaluation into pharmaceutical manufacturing and clinical product assessment helps identify contamination that could otherwise cause inflammatory or systemic reactions.

Detecting pyrogens supports prevention of product-associated fever and inflammation. The overview also identifies hypotension and potentially life-threatening systemic reactions as possible consequences of exposure. By evaluating relevant medical products before use, testing helps reduce the chance that contaminated injectables, biologics, or devices will trigger these unwanted responses during clinical care.